AU Patent

AU2020267194B2 — Dosage regimen for a S1P receptor agonist

Assigned to Novartis AG · Expires 2022-09-01 · 4y expired

What this patent protects

S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

USPTO Abstract

S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020267194B2
Jurisdiction
AU
Classification
—
Expires
2022-09-01
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.